Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. (2014)
Attributed to:
MICA: MRC Centre for Neuromuscular Diseases
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1474-4422(14)70195-4
PubMed Identifier: 25209738
Publication URI: http://europepmc.org/abstract/MED/25209738
Type: Journal Article/Review
Volume: 13
Parent Publication: The Lancet. Neurology
Issue: 10
ISSN: 1474-4422